Updated hourlyHourly refreshSat, Oct 31, 2026
SaaS
U.S. Laboratory Informatics Market to Reach USD 2.18 Billion and Europe USD 1.64 Billion by 2035 as Automation, Data Integration, and Regulatory Compliance Drive Demand.
U.S. Laboratory Informatics Market to Reach USD 2.18 Billion and Europe USD 1.64 Billion by 2035 as Automation, Data Integration, and Regulatory Compliance Drive Demand.
Aug 27 · 15:00·GlobeNewswire
AI · SaaS
SAN JOSE, Calif., August 27, 2026--Hark today announced a multi-year strategic partnership with NVIDIA to advance personalized agentic AI, including a deep technical collaboration and gigawatt-scale compute capacity on the next-generation NVIDIA Vera Rubin platform.
Aug 27 · 15:00·Business Wire
Finance · SaaS
HONG KONG, August 27, 2026 - CanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately RMB 550 million, up 43.8% year on year, while its net loss attributable to shareholders narrowed significantly. Notably, while demand in China’s vaccine market remains challenging, CanSinoBIO’s international business maintained strong growth momentum, generating overseas revenue of RMB 150 million during the reporting period.
As established products accelerate their expansion into overseas markets, and collaboration models such as technology partnerships and localized industrialization continue to take shape, CanSinoBIO’s overseas business is evolving from a strategic initiative into an increasingly important contributor to the Company’s performance. This reflects the Company’s forward-looking understanding of global vaccine market trends and evolving demand in international markets.
At a time when the vaccine industry is facing changes in demand structure, the combination of domestic innovation capabilities and access to international markets is becoming an increasingly important measure of corporate growth resilience.
Overseas Growth Accelerates
In the first half of 2026, China’s vaccine industry continued to face demand-side pressure. As the target population for infant and young-child vaccination continues to decline, demand pressure on traditional pediatric vaccines has become increasingly visible. “Volume contraction and price decline” has emerged as a widespread challenge across the industry.
Based on disclosed financial results across the sector, this pressure appears to be industry-wide. In 2025, Zhifei Biological generated RMB1.187 billion in revenue from self-developed products, up 1.23% year on year. Walvax Biotechnology reported 2025 revenue of RMB2.418 billion, down 14.29% year on year; despite a 53.36% year-on-year increase in batch-release volume for its core 13-valent pneumococcal conjugate vaccine, revenue remained under pressure. Kangtai Biological reported revenue of RMB1.273 billion in the first half of 2026, down 8.55% year on year.
Against this industry backdrop, the growth of CanSinoBIO’s international business is particularly noteworthy. The Company reported overseas revenue of RMB 150 million in the first half of 2026. This growth was driven, on the one hand, by the continued expansion of mature products into overseas markets and, on the other, by the further deepening of the Company’s international partnership models. For CanSinoBIO, this also means that its products, manufacturing processes and quality control capabilities, validated in the domestic market, are beginning to unlock value overseas through more diversified approaches.
Meanwhile, the Company continues to advance its international market footprint. Registration filings and commercialization efforts remain underway across Southeast Asia, South America and the Middle East. Menhycia(R) has obtained registration approvals in Indonesia and Argentina, and product supply has already commenced in Indonesia. As more products progress through overseas registration and commercialization, CanSinoBIO’s international business is expected to develop more diversified revenue streams and further strengthen its commercial resilience.
From this perspective, CanSinoBIO’s globalization strategy is evolving. Overseas markets are no longer merely destinations for mature products, but are increasingly becoming markets in which products, technologies and industrial capabilities can jointly create value. For an innovative vaccine company, this shift from “exporting products” to “exporting capabilities and systems” creates greater room for long-term growth in its overseas business.
Portfolio Upgrades Strengthen the Commercial Foundation
Sustained overseas expansion is underpinned by a stable product portfolio and strong technological capabilities.
According to the Company’s interim report, domestic revenue continued to grow despite factors such as changes in value-added tax, reflecting opportunities created by ongoing innovation. Menhycia(R), China’s first quadrivalent meningococcal conjugate vaccine, expanded its indicated population in February to children aged 3 months to 6 years, broadening its addressable population. Meanwhile, iPneucia(R), a 13-valent pneumococcal conjugate vaccine featuring dual-carrier technology (CRM197/TT), offers a differentiated option for pediatric pneumococcal disease prevention in China. Since its launch in September 2025, iPneucia(R) has continued to expand market access and is now available in nearly 30 provincial-level markets across China.
From meningococcal disease to pneumococcal disease, CanSinoBIO is using innovative products to address vaccine segments that continue to offer meaningful unmet demand. As traditional vaccine categories face pressure on volumes, structural growth driven by product and technology upgrades is providing important support for the Company’s commercial resilience.
More importantly, the product-development and industrialization capabilities established in the domestic market also provide a foundation for overseas expansion. For an innovative vaccine company, successful commercialization in China not only broadens revenue sources, but also validates the manufacturing, quality-control and supply systems required to replicate and extend those capabilities into international markets.
Domestic product upgrades and overseas business growth are thereforeclosely connected rather than separate. The former provides the foundation in products and technologies, while the latter expands the geographic boundaries within which those products can realize their value.
Multi-Layered Pipeline Takes Shape to Support Future Growth
For an innovative vaccine company, long-term growth depends not only on the commercial performance of existing products, but also on the ability to maintain a steady flow of new products. By pursuing continued ramp-up of marketed products, advancing products under regulatory review and developing next-generation candidates, CanSinoBIO is building a more sustainable and well-sequenced product pipeline.
Tripecia(R) (DT3cP Infant), CanSinoBIO’s three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received NDA approval in April 2026, becoming the first approved three-component DTP vaccine in China. In August 2026, the first commercial batches received the Certificate for Batch Release of Biological Products. Provincial tendering and market-access processes are progressing in an orderly manner, and the product has begun entering the market supply stage.
While Tripecia(R) represents an upgrade in pertussis vaccination for infants, the Td5cp vaccine for adolescents and adults — which has also been granted Priority Review status — is expected to extend CanSinoBIO’s pertussis vaccine portfolio to a broader population. The New Drug Application for Td5cp has been accepted by China’s National Medical Products Administration (NMPA).
In addition, CanSinoBIO’s independently developed Adsorbed Tetanus Vaccine, Tetcia(R), has been formally approved, further strengthening the Company’s adult vaccine portfolio. From infants to adolescents and adults, and from individual products to a multi-product portfolio, this strategy is broadening the foundation for future commercial growth.
In pneumococcal vaccines, CanSinoBIO’s 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV24) formally initiated Phase I/II clinical trials in May 2026, and participant enrollment across different cohorts is progressing as planned. At the same time, the Company continues to advance development of its DT3cP-Hib-MCV4 combination vaccine, extending its portfolio toward increasingly multivalent and combination vaccine formats.
Over the longer term, CanSinoBIO is continuing to build its mRNA platform and explore applications in preventive vaccines and therapeutic biologics. The Company is conducting early-stage research into mRNA applications for glioblastoma, rhabdomyosarcoma and cervical cancer, while also exploring in vivo CAR therapies. These programs remain at an early stage, with the Company continuing to assess the potential of mRNA and related technologies in disease treatment. Additionally, on August 25, CanSinoBIO announced that its subsidiary, CanSino Shanghai, had entered a strategic collaboration with deepGeneAI on mRNA therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the development and commercialization of personalized mRNA therapeutic cancer vaccines.
These pipeline programs represent extensions of CanSinoBIO’s existing technology platforms and product-development experience. The Company’s core platforms — including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, as well as formulation and delivery technologies — provide a foundation for continued product iteration and technology translation.
Innovation Supports Long-Term Development
Viewed in the context of its 2026 interim results, CanSinoBIO’s story is not simply one of revenue growth.
Against a changing domestic vaccine demand structure, innovative products have continued to deliver solid commercial performance, demonstrating the resilience created by product upgrades. Overseas business model expanded beyond finished-product exports to include technology collaboration and local manufacturing capabilities, indicating that international markets are becoming a new source of growth. At the same time, Tripecia(R) has entered the market supply stage, the Td5cp vaccine for adolescents and adults is progressing through regulatory review, and pipeline programs including PCV24, multivalent and combination vaccines, and mRNA technologies continue to advance, providing both product succession and technology reserves for the future.
These three pathways ultimately point to the same growth logic: domestic innovation capabilities form the product foundation, overseas expansion broadens the commercial opportunity, and sustained R&D determines whether growth can continue over the long term.
In an environment where demand for traditional vaccines is under pressure and industry competition is intensifying, growth is increasingly shifting away from reliance on product-volume expansion alone and toward a model jointly driven by product upgrades, technological innovation and global markets. For CanSinoBIO, continued growth in the overseas business is providing increasingly visible financial evidence of this transition.
As more innovative products enter the market, more mature products expand overseas and the Company’s technical capabilities extend further into international value chains, CanSinoBIO’s growth runway is expanding from a single domestic market to the global market. For the Company, internationalization is not only about broadening geographic reach; it is also an important pathway for innovative products and technologies to realize greater commercial value while contributing to global public health.
Aug 27 · 14:08·ACN Newswire
Finance · AI
New York, New York--(August 27, 2026) - The Remarkable Agency has expanded its offering for established SaaS, AI and subscription businesses that have outgrown fragmented marketing tactics. The firm now runs paid acquisition, performance creative, search and AI-search optimization, conversion optimization, lifecycle marketing and fractional marketing leadership as one connected growth system rather than as separate engagements.The timing reflects a shift in how growth-stage...
Aug 27 · 14:00·Newsfile
SaaS
NVIDIA’s Gamescom announcements are revealing what’s next for GeForce NOW, with new ways to play, more supported devices and platforms, and even more big PC games headed to the cloud. New NVIDIA DLSS 4.5 technology controls give members more ways to fine-tune gameplay, while expanded support for new Steam devices, GOG single sign-on, Firefox browser […]
Aug 27 · 13:00·NVIDIA
AI · SaaS
Key Takeaways Agent deployments more than doubled over the past year, according to Salesforce’s platform data, and those agents are driving real results. Retailers running AI agents grew online sales at four times the rate of those that didn’t. For the many organizations now deploying their first agents, that raises a sharper question: Among those […]
Aug 27 · 13:00·Salesforce
AI · SaaS
Detroit, Michigan--(August 27, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX) (the "Company"), a developer and operator of AI-driven security and productivity solutions for enterprise clients, along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced that RAD received orders for 14 units across five customer relationships during a single 24-hour period, marking the most diverse day of order intake in RAD history in...
Aug 27 · 12:40·Newsfile
Finance · SaaS
Authentic acquires majority stake in OVO intellectual property, with Drake retaining significant ownership NEW YORK, Aug. 27, 2026 -- Authentic Brands Group ("Authentic"), a global brand and entertainment platform, today announced the acquisition of a majority stake in the...
Aug 27 · 12:15·PR Newswire
AI · SaaS
Growth shows increased demand for unified platforms that connect every department in local and state government SAN FRANCISCO, Aug. 27, 2026 -- OpenGov, the company powering the AI platform for local and state government, today announced continued expansion of its government...
Aug 27 · 12:15·PR Newswire
Finance · AI
VANCOUVER, British Columbia, Aug. 27, 2026 -- ZenaTech, Inc. (Nasdaq: ZENA) (“ZenaTech” or the “Company”), a technology company specializing in AI-powered drones, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces it has been named the winner of the “Drone Technology of the Year” award in the 2026 AgTech Breakthrough Awards program.
Aug 27 · 12:15·GlobeNewswire
Finance · SaaS
ALPHARETTA, Ga., August 27, 2026--Agilysys, Inc. (Nasdaq: AGYS), a global hospitality-focused technology provider, today announced that more than 100 golf properties have deployed its industry-leading Agilysys Golf solution. The milestone reflects rapid adoption of Agilysys Golf, a modern golf management platform, across the golf industry, from premier resorts and destination golf properties to private clubs and membership organizations.
Aug 27 · 12:05·Business Wire
SaaS · Healthcare
REMOTE-FIRST COMPANY/TAMPA, Fla., August 27, 2026--NextGen Healthcare’s Behavioral Health Suite has been named the No. 1 platform for independent behavioral health practices in the Black Book Market Research Q3 2026 Behavioral Health EHR and Practice Management Platform Rankings for Independent Ambulatory Practices. This ranking is based on feedback from over 660 verified users representing 101 independent behavioral health organizations.
Aug 27 · 12:05·Business Wire